FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed

The FDA declined to approve Akeso's lung cancer drug ivonescimab, developed with Summit Therapeutics, due to insufficient evidence of improved survival in trials. The drug delayed cancer progression but did not meet statistical survival requirements. Summit plans further trials, and Akeso retains rights in China. AstraZeneca invested $2B in Summit for ivonescimab's development.

Original reporting
Published Nov 16, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed — source image
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The FDA declined approval because the HARMONi trial did not establish a statistically significant overall-survival improvement, despite favorable medians for progression-free timing and overall survival.

02

Market read

A U.S. regulatory denial for a lead oncology asset is a high-impact catalyst that can reprice approval probability, development timelines, and partner/investor expectations.

03

What to watch

The article notes longer follow-up analyses were not persuasive to the FDA, but it does not quantify how much additional follow-up could change statistical outcomes in the next trial, nor does it detail any planned protocol or endpoint adjustments for HARMONi-3.

Relevance 9/10Novelty 9/10Timing: FDA response letter disclosed Nov. 15, with Summit pursuing an alternative U.S. route via HARMONi-3.

Background

Ivonescimab (Akeso) is approved in China for certain advanced lung cancer settings and had earlier international attention from a China-only trial (HARMONi-2) versus Merck’s Keytruda; the FDA decision concerns a separate international Phase III trial (HARMONi).

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

Summit Therapeutics’ FDA submission for ivonescimab plus chemotherapy was rejected in its current form after the HARMONi Phase III trial failed to show statistically significant overall-survival improvement.

Expected impact

Likely pressure as the market discounts U.S. approval odds for the current regimen and focuses on the next trial path (HARMONi-3).

Evidence & confidence

The article ties the rejection directly to Summit’s application and cites the FDA’s stated requirement for statistically significant overall survival.

Market effects

Highlights heightened FDA evidentiary thresholds for oncology survival endpoints and the market’s sensitivity to trial-readout statistical significance.

Reinforces U.S. scrutiny of foreign clinical-trial data, potentially affecting sentiment toward other China-developed oncology programs seeking U.S. approval.

May influence global biotech risk models for cross-border development and the perceived approval pathway for China-origin assets in the U.S.

Counterpoint

The rejection is for the current HARMONi regimen and evidence set; Summit is already pursuing HARMONi-3, which could produce a different comparative design and survival readout.

Key entities

  • Akeso

    China-developed ivonescimab; FDA non-approval in the U.S. is a direct negative for its global development value.

  • Summit Therapeutics

    U.S. licensee that filed the FDA application and received the response letter declining approval in its current form.

  • FDA

    Issued a response letter stating the application could not be approved due to insufficient overall-survival evidence.

  • AstraZeneca

    Completed a $2 billion investment in Summit to support further development of ivonescimab.

Related articles

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$MDCXMed

Small cap wrap: Phunware, Trust Stamp, Medicus Pharma, TNR

TNR Gold (TSX-V:TNR, OTC:TRRXF) agreed to a $122M acquisition by Altius Minerals at a 60% premium. Grey Matters Health (CSE:GREY, OTCQB:AGNPD) gained Medicare/Medicaid accreditation. Snail Inc (NASDAQ:SNAL) received a positive analyst note after Q3 revenue growth. Summit Therapeutics (NASDAQ:SMMT) shares fell 12.69% after FDA rejection. Citi initiated coverage of Amaroq Minerals (AIM:AMRQ, TSX-V:AMRQ) with a 'buy' rating. BioVie (NASDAQ:BIVI, NASDAQ:BIVIW) presented Long COVID trial findings.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.